📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Medicamen Biotech Q3 Net Profit Drops 19% to ₹1.63 Cr; Revenue Up Slightly to ₹47 Cr
Medicamen Biotech reported a consolidated net profit of ₹1.63 crore for the quarter ended December 31, 2025, representing a 19.1% decline from ₹2.02 crore in the same quarter last year. Total revenue saw a marginal increase of 2.6% year-on-year, reaching ₹47.04 crore. Despite the quarterly dip, the nine-month performance remains positive with a net profit of ₹5.31 crore compared to ₹4.69 crore in the previous year. The company also announced the cessation of two independent directors following the completion of their tenures.
Key Highlights
Consolidated Total Revenue grew slightly to ₹47.04 crore in Q3 FY26 from ₹45.83 crore in Q3 FY25.
Consolidated Net Profit for the quarter fell to ₹1.63 crore, down from ₹2.02 crore in the previous year.
Earnings Per Share (EPS) decreased significantly to ₹1.21 from ₹2.30 in the corresponding quarter.
Nine-month consolidated net profit showed improvement at ₹5.31 crore versus ₹4.69 crore YoY.
Independent Directors Harish Pande and Arun Kumar completed their 10-year tenures effective February 13, 2026.
💼 Action for Investors
The quarterly performance indicates margin pressure as profits declined despite stable revenues. Investors should monitor cost management strategies and the impact of board committee reconstitutions on future governance.
Medicamen Biotech Q3 Consolidated Net Profit Falls 19% to ₹1.63 Cr; Revenue Up 2.6% YoY
Medicamen Biotech reported a consolidated total revenue of ₹47.04 crore for Q3 FY26, representing a modest 2.6% growth compared to ₹45.83 crore in the same quarter last year. However, consolidated net profit for the quarter declined by 19.1% YoY to ₹1.63 crore, down from ₹2.02 crore, as subsidiary performance weighed on the bottom line. On a standalone basis, the company performed better with a net profit of ₹2.59 crore. The company also announced the retirement of two independent directors and the subsequent reconstitution of key board committees.
Key Highlights
Consolidated Total Revenue increased by 2.6% YoY to ₹47.04 crore in Q3 FY26.
Consolidated Net Profit declined 19.1% YoY to ₹1.63 crore from ₹2.02 crore.
Standalone Net Profit grew slightly by 2.7% YoY to ₹2.59 crore.
Consolidated EPS for the quarter dropped to ₹1.21 from ₹2.30 in the previous year.
Independent Directors Mr. Harish Pande and Mr. Arun Kumar retired after completing two 5-year terms.
💼 Action for Investors
Investors should be cautious as the consolidated profit is significantly lower than standalone profit, indicating losses or high expenses in subsidiaries. Monitor the company's ability to turn around subsidiary operations to improve overall group margins.
Medicamen Biotech Receives EU Approval for Paracetamol Registration in Denmark
Medicamen Biotech Limited has successfully obtained product registration approval for Paracetamol from the Danish Medicine Authority. This approval was secured in collaboration with XGX Pharma, Denmark, marking a significant step into the European Union market. The registration validates the company's adherence to stringent EU manufacturing and quality standards. This development is expected to enhance the company's export capabilities and revenue potential within regulated international markets.
Key Highlights
Received EU approval for Paracetamol product registration from the Danish Medicine Authority.
Collaborated with XGX Pharma, Denmark, to facilitate the registration process.
Demonstrates compliance with high-level European pharmaceutical regulatory standards.
Strengthens the company's presence and growth prospects in the European market.
💼 Action for Investors
Investors should view this as a positive regulatory milestone that could drive future export growth. Monitor the company's progress in commercializing this product and seeking further approvals in other EU territories.